Researchers at Massachusetts General Hospital and Harvard Medical School have developed machine learning-based methods to predict which patients with early-stage melanoma have the highest risk for disease recurrence.The methods could help reveal those who may benefit from greater surveillance or adjuvant immunotherapy, the investigators wrote in a study published in npj Precision Oncology.